In-Vitro and Ex-Vivo Investigations of the Microtubule Binding Drug Targetin on Angiogenesis

Area of Science:

• Oncology
• Vascular Biology
• Pharmacology

Background:

• Angiogenesis is crucial for cancer progression, making anti-angiogenic therapies a key strategy.
• Hypoxia-inducible factor-1α (HIF-1α) activation under hypoxia drives vascular endothelial growth factor (VEGF) production, promoting tumor angiogenesis.
• Microtubule dynamics are implicated in HIF-1α processing, suggesting microtubule-targeting agents as potential anti-angiogenic drugs.

Purpose of the Study:

• To investigate the anti-angiogenic and vascular-disrupting potential of Targetin, a novel noscapinoid.
• To evaluate Targetin's effects on endothelial cell function and neovasculature formation.

Main Methods:

• In vitro and ex vivo angiogenic models were employed.
• Targetin's effects on human endothelial cell networks and rat aortic explant sprouting were assessed.
• Experiments were conducted with and without proangiogenic stimuli like VEGF and basic fibroblast growth factor (bFGF).

Main Results:

• Targetin demonstrated significant vascular-disrupting and anti-angiogenic properties.
• It severed cell-cell junctions in pre-assembled capillary-like networks of human endothelial cells.
• Targetin inhibited endothelial cell proliferation and metabolic activity, and suppressed neovasculature network sprouting.

Conclusions:

• Targetin exhibits potent anti-angiogenic and vascular-disrupting activities.
• The compound effectively inhibits endothelial cell function and neovascularization.
• Targetin represents a promising therapeutic candidate for treating angiogenesis-dependent diseases, including various cancers.